It took Bristol Myers Squibb’s new CEO Chris Boerner 16 minutes into his 24-minute presentation to address the big news the company made last month, with its holiday buyouts of Karuna Therapeutics, ...

Monday - Friday, 6:00 - 7:00 PM ET Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant's slew of recent acquisitions in a Monday interview with CNBC's Jim Cramer. Boerner ...

(Reuters) -Bristol Myers Squibb's new chief executive said on Friday that the company was focused on driving growth toward the end of the decade but would first need to weather a difficult transition ...

Amid the sturm und drang over Inflation Reduction Act (IRA) drug price negotiations, Bristol Myers Squibb has been among the biopharma companies casting the most woe over the oncoming measures.

Bristol-Myers Squibb's second quarter saw flat overall sales, but the company surpassed Wall Street expectations for both revenue and non-GAAP profit, with operating margin improving year on year.

Rachel Cohrs Zhang reported on the intersection of health policy and business in Washington. She covered Capitol Hill, lobbying, and federal agencies. Her primary areas of focus were the ...

Bristol Myers Squibb is not fully switching out of the buyer’s lane just yet after ending 2023 on a deal spree, but CEO Chris Boerner, Ph.D., said bolt-on moves are more likely the company’s speed in ...

Monday - Friday, 6:00 - 7:00 PM ET Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenfy, which can be used to treat psychiatric disorders like schizophrenia. He said the ...

Bristol-Myers Squibb CEO Chris Boerner detailed the pharmaceutical giant's bundle of recent acquisitions in a Monday interview with CNBC's Jim Cramer, and indicated the company is in a transformative ...

Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed products. Management highlighted strong ...